Endologix, Inc. (ELGX) News
Filter ELGX News Items
ELGX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest ELGX News From Around the Web
Below are the latest news stories about Endologix Inc that investors may wish to consider to help them evaluate ELGX as an investment opportunity.
Endologix plunges 41% after filing for Chapter 11After evaluating a variety of strategic options, Endologix (ELGX) has initiated a voluntary case under Chapter 11 of the U.S. Bankruptcy Code and simultaneously filed a consensual plan of reorganization supported by Deerfield Partners as its largest creditor.The financial reorganization would reduce ~$180M in debt and will provide an ~$30M in additional exit financing.Endologix also... |
Endologix's stock plunges toward record low after bankruptcy filingShares of Endologix Inc. plunged 41% toward a record low in premarket trading Monday, after the medical device maker filed for bankruptcy over the weekend, and announced a deal to be taken private by its largest creditor Deerfield Partners. The company said the reorganization will reduce debt by about $180 million. Endologix also expects $30.8 million in debtor-in-possession financing from Deerfield, an additional $30 million in exit financing from Deerfield and $50 million in rolled over debt. Endologix said it fully intends to meet its financial obligations during the reorganization, including paying its suppliers. The stock had rallied 20.3% over the past three months through Thursday but had tumbled 51.3% year to date, while the S&P 500 has lost 3.1%. |
Endologix Enters into an Agreement with Deerfield Partners to Take the Company PrivateEndologix Enters into an Agreement with Deerfield Partners to Take the Company Private |
Sight Sciences Strengthens Its Leadership Team with Chief Operating Officer and General Counsel HiresSight Sciences, Inc., a growth-stage medical device company transforming the two fastest-growing segments in ophthalmology and optometry, glaucoma and dry eye disease, today announced two key hires: Sam Park, joining as Chief Operating Officer, and Jeremy Hayden, who joins as General Counsel and Chief Compliance Officer. |
Edited Transcript of ELGX earnings conference call or presentation 11-May-20 8:30pm GMTQ1 2020 Endologix Inc Earnings Call |
Endologix finance chief bids adieuEndologix ([[ELGX]] -1.5%) CFO Vaseem Mahboob will leave the company effective July 1.VP, Financial Planning & Analysis Cindy Pinto will take over on an interim basis until a permanent successor is named.... |
Endologix Announces Departure of CFO and Appointment of Interim CFOIRVINE, Calif.--(BUSINESS WIRE)--Endologix, Inc. (Nasdaq: ELGX) (“Endologix” or the “Company”), a developer and marketer of innovative treatments for aortic disorders, today announced that Vaseem Mahboob, Chief Financial Officer (CFO), will be departing the Company effective July 1, 2020 to become CFO of a private global healthcare company. Cindy Pinto, Vice President, Financial Planning & Analysis, will assume the role of interim Chief Financial Officer in addition to her current responsib |
Endologix Issues Correction Notice for Ovation iX Abdominal Stent Graft SystemIRVINE, Calif.--(BUSINESS WIRE)--Endologix® Inc. (Nasdaq: ELGX) (“Endologix” or the “Company”), a developer and marketer of innovative treatments for aortic disorders, today announced that a correction notice has been issued for the Ovation iX system, that identifies the root cause of polymer leaks. This voluntary action has been classified by the FDA as a Class 1 recall. No physical product removal of the product is planned or needed. Correction Z-2263-2020 was issued in May 2020 to current us |
9th Circuit rejects stock-drop claims against device withdrawn from FDA approvalA federal appeals court has affirmed the dismissal of a proposed class action lawsuit accusing medical device maker Endologix Inc and its executives of concealing serious problems with its Nellix aneurysm sealing device from investors, resulting in a sharp stock drop when it revealed the product would not receive FDA approval. |
Hedge Funds Never Been Less Bullish On Endologix, Inc. (ELGX)The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 821 13F filings submitted by hedge funds and prominent investors. These filings show these funds' portfolio positions as of March 31st, 2020. […] |